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The human immunodeficiency virus type 1 (HIV-1) is notorious for its ability to evolve drug-resistance in patients treated
with potent antivirals. Resistance to inhibitors of the viral reverse transcriptase (RT) enzyme is frequently mediated by a
single amino acid substitution within RT. Resistance against the nucleoside analogue AZT is remarkable in that multiple amino
acid changes accumulate over time to yield virus variants with high-level drug resistance. We now report that in addition to
drug-resistance properties, the relative replication capacity of the virus variants affects the evolution of AZT resistance.
Some of the typical AZT-resistance mutations have a negative impact on virus replication, and the 41-70 double mutant was
found to represent a particularly poor virus. Furthermore, introduction of additional AZT-resistance mutations (41-70-215)
leads to nearly complete restoration of virus replication. These results may explain the absence of the 41-70 double mutant
in clinical samples and indicate that the evolution of AZT resistance is also influenced by virus replication parameters.
Prolonged passage of the replication-impaired 41-70 virus in the absence of AZT yielded several fast-replicating variants.
These revertants have compensatory changes in the RT polymerase, some of which have been observed previously in
AZT-treated patients. Because we could select for these changes without drug pressure, these changes are likely to improve
the RT enzyme function and the HIV-1 replication capacity. © 2001 Academic Presst
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Reverse transcriptase (RT) is an essential enzyme of
all retroviruses and hepadnaviruses, and this polymer-
ase has become a major target for the development of
antiviral drugs. Several classes of inhibitors of the RT
enzyme of the human immunodeficiency virus (HIV-1) are
currently in clinical use (Emini and Fan, 1997), and some
of these drugs also appear effective against hepatitis B
virus (HBV) (Schinazi et al., 1994; Furman et al., 1992).
The benefits of antiviral drug therapy are limited because
of the emergence of drug-resistant virus variants, which
has been observed both for HIV-1 (Larder and Kemp,
1989; Larder et al., 1991) and HBV (Allen et al., 1999; Ling
et al., 1996). For HIV-1, combination therapy with multiple
RT and protease inhibitors can almost completely sup-
press virus replication and thus prevent the development
of drug-resistant variants in most patients. However,
drug toxicity problems and the appearance of multi-drug-
resistant HIV-1 have complicated combination chemo-
therapy considerably (Emini and Fan, 1997).
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294Previous studies have reported that some drug-resis-
tant HIV-1 variants exhibit reduced replication due to the
mutations within the RT and/or protease enzymes. For
instance, the nucleoside analogue 3TC selects for HIV-1
variants with a point mutation within the well-conserved
YMDD catalytic domain of the RT enzyme, and these
YIDD or YVDD variants exhibit reduced polymerase ac-
tivity and replication capacity (Boyer and Hughes, 1995;
Back et al., 1996). Strikingly similar drug-resistance mu-
ations have been described for HBV variants that are
elected in 3TC-treated individuals (Allen et al., 1999;
ing et al., 1996), and a concomitant loss of replication
apacity has also been reported (Melegari et al., 1999;
Ono-Nita et al., 1999). Unlike the 3TC situation, the evo-
lution of protease drug resistance is accompanied by
multiple mutations within the protease function (Molla et
l., 1996). There is accumulating evidence that the pri-
ary resistance-inducing mutations within the protease
ause a loss of enzymatic function and a significant
eplication defect. Secondary mutations can compensate
or this defect, and these compensatory changes occur
ithin either the enzyme itself, the target cleavage sites
ithin the Gag polyprotein precursor, or the Gag–Pol
rameshift site (Croteau et al., 1997; Doyon et al., 1998;
Carron de la Carriere et al., 1999; Mammano et al., 1998;
Zennou et al., 1998). Thus, a complex interplay of param-
eters, including drug resistance and catalytic properties
of the variant enzyme, direct the evolution of protease-
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295AZT RESISTANCE IN HIV-1drug resistance (Berkhout, 1999). Additional factors such
as HIV-1 population dynamics control the level of genetic
variation and can thereby also influence the evolution of
drug resistance (Coffin, 1995; Keulen et al., 1997; Nijhuis
et al., 1998).
A similarly complex evolutionary pathway occurs dur-
ing the acquisition of resistance to the nucleoside ana-
logue 39-azido-39-deoxythymidine (AZT). Six amino acid
changes that are frequently observed in AZT-resistant
HIV-1 variants are shown in Fig. 1 (M41L, D67N, K70R,
L210W, T215Y/F, and K219Q). Although the order of ap-
pearance of these mutations can differ among patients,
some general trends can be recognized (Boucher et al.,
1992; Kellam et al., 1992; Cleland et al., 1996). Some of
he resistance-associated mutations appear relatively
arly, e.g., M41L and K70R, and both individual changes
rovide a low level of AZT resistance. Other changes are
FIG. 1. Schematic of the pathway of AZT-resistance development by
ccumulation of mutations in the HIV-1 RT protein. Indicated are the six
mino acid positions that are most frequently associated with AZT
esistance. The order of appearance of the different mutations varies
ignificantly in individual patients, but some general features are in-
orporated in this schematic. In general, evolution will start with a
ingle change (e.g., K70R), and the type of mutation is one factor that
ffects the likelihood. For instance, the K70R mutation represents a
elatively easy one-nucleotide transition (codon ATG to TTG or to CTG),
whereas both the T215Y and the T215F changes represent a much
more difficult two-nucleotide substitution (codon ACC to TAC and TTC,
respectively) that will occur relatively infrequently. This is schematically
depicted. Additional amino acid changes are introduced within these
mutants either by mutation or by recombination with other virus vari-
ants. Several potential intermediate genomes that were constructed
and tested in this study are indicated. The 41-70 double mutant that is
not observed in clinical samples (the missing link) is marked by a gray
box.bserved almost exclusively at later times, e.g., T215Y/F, ind provide a high level of AZT resistance in combina-
ion with the other mutations (Larder, 1994). One reason
or the differences in time of appearance of the different
T changes is the type of mutation that is required to
hange the codon sequence (Keulen et al., 1996). For
nstance, whereas a relatively simple transition or trans-
ersion is required for the AZT-resistance mutation at
odon 41 and 70, respectively, a rather difficult two-
ucleotide transversion is required at codon 215.
A remarkable feature of AZT-resistance development
s the apparent absence of the HIV-1 intermediate with
he 41-70 double mutation in “early” treatment clinical
amples, even though these two changes do coincide at
ater stages of treatment once additional RT changes
ave been acquired, in particular the 215 mutation (Fig.
). These results indicate that complex interactions as
een in the development of protease drug resistance
ay also play a role in the evolution of AZT resistance. In
articular, these results may suggest that the 41-70
missing link” (marked in gray in Fig. 1) is not observed
ecause of a replication defect. The alternative explana-
ion is that the 41-70 intermediate does not provide drug
esistance. To test for the virus replication phenotype, we
ade HIV-1 constructs with the 41-70 double mutation
nd several control viruses. The 41-70 virus exhibits a
rofound replication defect, which could be linked to an
nusual activity of the RT enzyme. Virus replication could
e repaired by inclusion of the late AZT mutation at
odon 215, which also restored the normal pattern of RT
ctivity. Prolonged replication experiments were per-
ormed to select for virus revertants with compensatory
mino acid changes. We identified multiple second-site
mino acid changes within RT that can restore the func-
ion of the 41-70 HIV-1 mutant. Several of these second-
ite changes cluster in the fingers–palm domains near
he catalytic core of the RT enzyme, e.g., the S163N
ubstitution, and other changes affect residues that have
een implicated in the interaction with the template
trand. Even though this in vitro evolution was performed
ithout AZT pressure, several of these second-site
hanges have also been observed in drug-treated pa-
ients. These combined results indicate that loss and
epair of virus replication capacity are important deter-
inants in the evolution route of AZT resistance.
RESULTS
he absence of the 41-70 RT double mutant during
volution of AZT resistance
We screened 112 RT sequences derived from 83 pa-
ients on AZT therapy that were sampled in the AMC
ospital. Samples were taken at variable times after the
tart of treatment, and some patients were followed lon-
itudinally. We analyzed the amino acid changes at po-
ition 41, 67, 70, 210, 215, and 219 (a survey is presentedn Table 1). The well-known resistance mutations were
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296 JEENINGA ET AL.observed in most cases, except that we also observed
several unusual amino acid changes at these positions.
For instance, several alternative substitutions were
present at position 67, 215, and 219. This large collection
of sequences was used for an initial screen of mutually
exclusive amino acid changes within RT. We observed a
general trend for the viruses having both the M41L and
the K70R mutation to contain additional AZT-resistance
mutations. In fact, we did not observe any 41-70 double
mutant without one of the additional changes in this
extensive set of HIV-1 sequences. Of the 32 sequences
with the combined 41-70 mutation, all samples also con-
tained the resistance mutations at position 67 and 215,
and the majority of samples also contained either the 210
mutation (153) or the 219 mutation (203).
The results of this analysis are biased because of the
fact that most samples were analyzed relatively late after
the start of therapy, as witnessed by the acquisition of
the 215 mutation in all but one sample. We therefore also
analyzed published sequence data on the occurrence of
AZT-resistance mutations in patients. A survey of the
Delta trial revealed that the mutation at codon 41 ap-
peared only after the acquisition of the 215 mutation
(Boucher et al., 1992; Larder, 1994; Keulen, 2000). This
mutual exclusion of amino acids that facilitate AZT resis-
tance is also apparent from a recent survey of 302
patients undergoing therapy (Yahi et al., 1999). In that
tudy, a mutation at codon 41 was rarely (,20%) asso-
iated with a mutation at codon 70, and this inverse
orrelation was statistically significant (P , 10 25). In
fact, other putative interactions between the AZT-resis-
tance mutations were also apparent from this study and
our own analysis. For instance, Yahi et al. (1999) reported
he apparent mutual exclusion of the mutations at
odons 70 and 210, which is consistent with previously
ublished results on the evolution of AZT-resistant geno-
ypes in treated patients (Cleland et al., 1996; Hooker et
l., 1996). The multiple sequence analysis presented in
his study revealed a possible coupling of changes at
T
HIV-1 RT Genotype o
Codon
Position 41
(n 5 112)
Position 67
(n 5 107)
wta 31 3 M 38 3 D
esistance mutation 80 3 L 62 3 N
Other changes 1 3 F 4 3 E
1 3 K
1 3 S
1 3 Gc
a wt is defined as the consensus sequence of subtype B HIV-1 isola
b Alternative AZT-resistance mutation.
c Co-variation 67-70 (see the text).osition 67 and 70 (Table 1: D67G and K70E). These fombined results indicate that there are multiple amino
cid interactions between the AZT-resistance positions
hat affect RT enzyme function either at the level of
olymerase activity and/or at AZT resistance. These mul-
iple fitness and resistance parameters, combined with
utational rates, translate into the complex multistep
volution of high-level AZT resistance (Koseki et al., 1999;
arrigan et al., 1998). We set out to test in further detail
he replication properties of HIV-1 with the 41-70 double
utation, the combination that seems to be excluded in
he absence of the other AZT-resistance mutations.
mpaired replication of the HIV-1 41-70 double mutant
We made a set of RT mutants in the context of the
olecular clone of the T-cell tropic HIV-1 isolate HXB-2.
he double-mutant 41-70 was specifically constructed to
est for its replication potential, but we also included the
orresponding early virus variants with a single mutation
41 and 70), the “late” variant with three mutations (41-
0-215), and several putative intermediates (e.g., 41-215
nd 70-215). In addition, we tested the two variants at
osition 215 that are known to provide AZT resistance
215Y and 215F, see also Table 1). The wt and nine
utant HIV-1 plasmids were transfected into nonsuscep-
ible C33A cells, and the culture supernatant was har-
ested at 3 days posttransfection as virus stock. A similar
evel of virus production was measured for the 10 con-
tructs (results not shown), indicating that there is no
efect in virus production. Equal amounts of virus (on the
asis of CA-p24 value) were used to infect the SupT1 T
ell line, and we monitored the level of virus spreading
hrough the culture by measuring CA-p24 production in
he culture supernatant (Fig. 2). Most HIV-1 mutants rep-
icated with kinetics similar to that of the wt control, but
elayed replication was apparent for the 70 mutant, and
n particular for the 41-70 double mutant. Replication can
e restored in these mutants by inclusion of the 215
utation. Similar results were obtained in multiple trans-
nts on AZT-Therapy
n 70
11)
Position 210
(n 5 112)
Position 215
(n 5 99)
Position 219
(n 5 104)
K 54 3 L 1 3 T 66 3 K
R 56 3 W 78 3 Y 21 3 Q
18 3 Fb 6 3 Eb
T 1 3 Y 1 3 I 9 3 N
Ec 1 3 S 1 3 D 1 3 R
1 3 C
yers et al., 1995).ABLE 1
f Patie
Positio
(n 5 1
52 3
57 3
1 3
1 3
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297AZT RESISTANCE IN HIV-1phocytes and in other T-cell lines (e.g., the MT2 T cell
line). We performed sensitive virus competition assays
(Koken et al., 1992) to verify some of the replication
effects observed in the course of this study. For instance,
we analyzed the composition of a mixture of the wt and
41-70 mutant after a few passages in SupT1 cells (Table
2, experiment A). There is rapid outgrowth of the wt virus,
even if the experiment was started with a wt:mutant ratio
of 10:90. A similar competitive advantage of the wt virus
over the 41-70 mutant is apparent in PBMCs (Table 2,
experiment B). This experiment also indicates that the wt
virus needs more time to compete with the 41-70-215
triple mutant, which is consistent with the finding that the
triple mutant replicates more efficiently than the double
mutant. These combined results indicate that the 41-70
virus has a significant replication defect, which can ex-
plain its absence during AZT treatment in vivo.
The replication defect of the 41-70 mutant virus is likely
to be caused by dysfunction or inactivity of the RT poly-
merase. We previously reported that such defect can be
T
Virus Compe
Mixture
SupT1 cells (exp. A) P
wt:41–70 wt:41–70
Input 50:50 10:90 50:50
Passage 1 90:10 25:75 90:10
Passage 2 100:0 20:80 100:0
FIG. 2. Replication kinetics of HIV-1 variants with single and multiple
AZT-resistance mutations. Virus stocks were produced by transfection
of nonsusceptible C33A cells with the respective molecular clones, and
an equal amount of virus (10 ng CA-p24) was used to infect the SupT1
T cell line. Virus replication was apparent by inspection of the cultures
for virus-induced syncytia, and virus spread was measured by CA-p24
ELISA at different days postinfection. A representative experiment is
shown, and similar results were obtained in four independent infec-
tions.Note. nd, not determined.measured with virion-extracted enzyme in an in vitro
reverse transcription assay with the poly(A)–oligo(dT)
template primer (Back et al., 1996). This assay measures
[32P]dTTP incorporation on the poly(A) template. The ad-
antage of this source of RT enzyme is that it is the
iologically relevant form of the HIV-1 RT heterodimer.
he disadvantage of this assay system is that it repre-
ents an unnatural, homopolymeric template primer. The
T enzyme was released by NP40 treatment of aliquots
f the 10 HIV-1 variants produced in C33A cells. The RT
nzymes were tested in four independent assays and
TTP incorporation was measured after a 1 and 2 h
eaction. The results are summarized in Fig. 3. We cor-
ected the RT activity for the amount of virus used in the
xtraction (CA-p24 values) and the value measured with
he wt RT enzyme was arbitrarily set at a value of 1.
urprisingly, we consistently measured increased RT ac-
ivity for the 41 mutant and in particular for the 41-70
ouble mutant. Interestingly, this effect is neutralized by
ddition of the 215 mutation as in the 41-70-215 triple
utant, which also restored virus replication. Further-
ore, we measured a small, but significant loss of RT
ctivity for the 215Y and 215F mutants, and this defect
as restored by inclusion of the 41 or 70 mutation.
We also analyzed the cDNA reaction products ob-
ained with all RT mutants on a sequencing gel to detect
otential differences in processivity of these poly-
erases. This assay is performed with the virion-ex-
racted RT enzyme and a huge excess of template
rimer, such that the RT enzyme is trapped once it
issociates from the template. Although processivity ef-
ects have been reported for other drug-resistant RT
utants that exhibit a polymerase defect (Back et al.,
996; Avidan and Hizi, 1998; Back and Berkhout, 1997),
e did not observe such differences for this set of RT
utants. The combined results of the virus replication
nd RT enzyme assays indicate that significant func-
ional defects are imposed by some of the early AZT-
esistance mutations (41 and 70, and in particular the
1-70 combination), and that the late 215 mutation can
estore replication to nearly wt levels.
xperiments
xp. B) SupT1 cells (exp. C)
wt:41–70–215 wt:rec #6
60:40 30:70 70:30 90:10
75:25 0:100 0:100 20:80
90:10 nd nd ndABLE 2
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298 JEENINGA ET AL.Prolonged culturing of the 41-70 mutant to select for
phenotypic revertants
The severe replication defect of the 41-70 double mu-
tant can explain its absence in clinical samples. This
result also indicates that the route toward high-level AZT
resistance may be more difficult than previously thought.
The 41-70 intermediate may present a bottleneck in the
evolution of AZT resistance, and this may explain why it
takes many months for full AZT resistance to develop in
vivo. Likewise, it has been particularly difficult to select
for AZT resistance in in vitro culture systems compared
with selection for resistance to other RT drugs (e.g., 3TC)
or protease drugs (Larder et al., 1989; Keulen et al., 1997,
1999). It is possible that the difficult two-hit mutation at
codon 215 restricts the evolution of AZT resistance
(Keulen et al., 1996), and this effect may be augmented in
the context of the poorly replicating 41-70 intermediate.
We performed one long-term culture with the 41-70 mu-
tant in the presence of AZT to test whether the other
resistance mutations evolve with this intermediate as
starting point of virus evolution. We also performed long-
term passage without AZT to select for spontaneous
revertants of this poorly replicating virus. The latter ex-
periment was performed to identify interesting second-
site changes within the RT enzyme. To detect multiple
repair routes, we performed the evolution experiment
without AZT in seven independent cultures (summarized
in Table 3).
Improved virus replication was observed over time in
all eight cultures. This is illustrated for culture 6 in Fig. 4,
in which we compare the replication kinetics of viruses
that were sampled over time. Identical amounts of input
virus based on the CA-p24 level were used in this ex-
periment. These results clearly demonstrate a gradual
increase in the replication potential of revertants over
FIG. 3. RT activity of the wt and mutant virus variants. Virus stocks pro
as analyzed in the poly(A)–oligo(dT) assay. Background activity obtain
alues obtained with the HIV-1 samples. The RT activity was standardiz
ere compared with the RT activity of the wt virus, which was arbitrar
nd the standard deviation is indicated. Similar results were obtained
T enzyme.time. Corresponding cell samples were used to isolateproviral DNA for sequence analysis. As expected, both
the 41 and 70 mutation were maintained in the evolution
experiment with AZT (culture 1). We next screened for the
acquisition of some of the additional AZT mutations at
position 67, 210, or 219, but these positions were not
altered. In the seven evolution experiments without AZT
(cultures 2 through 8), we initially screened for the dis-
appearance of AZT-resistance mutations at position 41
and 70, but we found these mutations to be stably main-
tained. We therefore sequenced a large part of the RT
genes. We found additional amino acid substitutions in
all RT samples, and frequently at positions that are well
conserved among natural HIV-1 isolates (Table 3).
To provide further evidence for the correlation be-
tween improved virus replication and these additional RT
mutations, we introduced the RT gene by recombination
in an HXB-2 background (Boucher et al., 1996). The
recombinant viruses demonstrated efficient replication in
SupT1 infections, as shown for the rec6 virus in Fig. 4.
We also PCR-amplified and sequenced the RT segment
of recombinant viruses corresponding to the cultures 1
through 7 (Table 3). For unknown reasons, we did not
manage to make the recombinant virus with the RT
material from culture 8. Different second-site RT changes
were detected in the individual cultures, suggesting that
multiple evolutionary routes can lead to improvement of
RT function and HIV-1 replication. Many of the changes
observed in the context of the malfunctioning 41-70 mu-
tant cluster around the catalytic core of the RT enzyme or
affect residues that are implicated in template binding
(see Discussion and Fig. 5).
We selected the rec6 virus for a more detailed analysis
of the RT reversion event. This virus is among the fastest
replicating revertants, which was confirmed in a direct
competition with the wild-type virus (Table 2, experiment
in C33A cells were treated with NP-40 to release the RT enzyme, which
culture supernatant from a mock transfection was subtracted from the
he amount of input virus (on the basis of CA-p24 value), and all values
t the value of 1. The results represent four independent experiments,
rified virus particles, obtained by ultracentrifugation, as source for theduced
ed with
ed for t
ily set a
with puC). Another interesting feature of the virus selected in
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tion by CA-p24 ELISA.
299AZT RESISTANCE IN HIV-1culture 6 is that the altered residue 163 is well-conserved
among natural HIV-1 isolates. Among 80 HIV-1 variants of
all subtypes, we scored a few changes at this position
(2 3 A, 1 3 T, 2 3 Y, and 1 3 N); the latter variation is
dentical to the one we selected in the 41-70 context.
mino acid 163 is positioned within the “palm” domain of
he RT enzyme and is in proximity of the catalytic core in
he closed structure of an elongating RT polymerase
Huang et al., 1998). Mutations within this region, e.g., at
osition 160, have been reported to grossly affect RT
nzyme function (Gutierrez-Rivas et al., 1999). The indi-
idual 163 codon change was introduced in the 41-70
ouble mutant, and the resulting 41-70-163 virus was
ested for replication on the SupT1 T cell line (Fig. 6).
ndeed, this mutation can explain at least in part the
henotypic reversion of the poorly replicating 41-70 vari-
nt into a fast-replicating virus. We also extracted the
orresponding RT enzymes from the virion particles for a
est of the polymerase function in the poly(A)–oligo(dT)
ssay (Fig. 7). The 163 mutation was able to restore the
nusually high activity of the 41-70 mutant to approxi-
ate wt levels. This finding suggests that the increased
ctivity of the 41-70 mutant in this in vitro assay does
orrelate with a loss of function during in vivo reverse
1–70 RT Mutant
Additional Mutations
R358K
Y271H P272A I293V R358K
L303M Y405H V417A
R284T
N447S
N447S
R284K
R284KTABLE 3
Evolution of the HIV-1 4
Culture No.
Day of
sampling
1a 91b none
122c V75I T200I
136d V75I T200I
2 133b,c F116L P176S
147d F116L P176S
3 103b V179I
134c V179I
148d P25A V179I
4 130b,c T165I
144d I135V T165I
5 72b none
112c none
126d P157S P176L
6 119b V35I
119c V35I S163N
143d V35I S163N
7 102b,c none
116d L283I
8 126b P157T C280S f
126c P157T
—e —e
a Cultured in presence of 0.1 mM AZT.
b Population sequence of RT codons 30–300.
c Population sequence of RT codons 1–560.
d Population sequence of recombinant virus (RT codons 1–560).
e No recombinant virus was obtained.
fFIG. 4. Growth kinetics of revertant viruses isolated at different time
points after infection. Frozen supernatant samples taken at days 54 and
113 posttransfection of the 41-70 double mutant in culture 6 were
analyzed for CA-p24 levels and subsequently used to infect SupT1
cells. The wt HXB-2 virus is included as a control. In addition, the PCR
fragment of the RT gene present at day 119 in culture 6 was recom-
bined into HXB-2 delta-RT and this recombinant virus (rec6) was also
analyzed. For all samples, equal amounts of input virus were used (2.5
ng CA-p24). Virus production was monitored at several days postinfec-ranscription in virus-infected cells.
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300 JEENINGA ET AL.We also inserted the codon 163 change in the wt
HXB-2 molecular clone. We found that this reversion-
causing mutation accelerates the replication of the wild-
type virus in this in vitro infection assay (Fig. 6). There is
accumulating evidence from different experimental sys-
tems that HIV-1 variants can be identified or selected that
outcompete the “wt” virus (Das et al., 1998; Nijhuis et al.,
1998; Caliendo et al., 1996; Koseki et al., 1999). It is
ossible that these results are caused by suboptimal
eplication of the wt control viruses in the in vitro culture
ystems. The intracellular pool of dNTPs varies signifi-
antly in different cell types, and a low dNTP level in
uiescent primary cells can negatively affect the process
f reverse transcription (O’Brien et al., 1994; Zack et al.,
992; Back and Berkhout, 1997; Pfeiffer et al., 1999). We
herefore also compared the different HIV-1 viruses in the
T2 cell line, which has a much lower dNTP level than
he SupT1 T cell line (unpublished results). Although the
FIG. 5. The X-ray crystal structure of HIV-1 RT of Huang et al. is show
omain (B) (Huang et al., 1998). This structure, containing both the dup
with the coordinated Mg21 ions as gray balls), represents the catalytic
view of the catalytic core. The position of the residues 41-70 are mark
with AZT are marked in red, and the changes acquired without AZT pres
from the Protein Data Bank and with the MOLSCRIPT (Kraulis, 1991) aeplication differences may seem less dramatic in this bell type, we observed the same order of replication
apacity: 163 . wt . 41-70-163 . 41-70 (Fig. 6). We also
nalyzed the corresponding RT enzyme with the S163N
hange in the poly(A)–oligo(dT) assay, but we measured
o significant difference compared with the wt enzyme
Fig. 7).
DISCUSSION
Inspection of HIV-1 sequences of patients on AZT
herapy indicates a complex evolutionary pathway to-
ard high-level resistance by acquisition of at least four
utations, and usually up to six mutations, in the RT
nzyme. In this evolution, some of the viral intermediates
re not observed, suggesting that negative interactions
ay occur between some of the AZT-resistance muta-
ions. In particular, we report the absence of the 41-70
ouble mutant in patient samples, even though this com-
the complete p66 subunit (A) and a tilted close-up of the fingers–palm
A (not shown) and the incoming deoxynucleotide triphosphate (shown
plex. The thumb domain is not included in B to have an unobstructed
reen. The additional changes that were selected in the 41-70 genome
re marked in yellow. The picture was drawn with the 1RTD coordinates
TER3D (Merritt and Bacon, 1997) programs.n, with
lex DN
RT com
ed in g
sure aination is present in high-level AZT-resistant variants
301AZT RESISTANCE IN HIV-1that have acquired additional resistance mutations. We
demonstrate that the 41-70 combination represents a
poorly replicating HIV-1 mutant. This variant evolves in
tissue-culture infections by acquisition of additional mu-
tations. The multiple evolution experiments performed in
this study indicate that there are numerous routes to
repair the 41-70 double mutant. The 41-70 amino acids
are highlighted in green in the structure model of the
catalytically active HIV-1 RT in Fig. 5 (Huang et al., 1998).
Some interesting mutations were observed in culture 1
under continuous AZT pressure (marked in red in Fig. 5).
The V75I change is a common resistance mutation, and
the T200I change has also been observed in AZT-treated
individuals (Stanford HIV RT and protease sequence
database at http://hivdb.stanford.edu/hiv/). Interestingly,
several drug-resistant isolates combine the two muta-
tions as in culture 1. Residue 75 is part of the fingers
domain of RT and interacts with the template through
hydrogen bonds (Huang et al., 1998).
Interesting RT amino acid changes were also selected
in the cultures without AZT (marked in yellow in Fig. 5).
FIG. 6. Replication kinetics of mutant/revertant viruses on SupT1 cells
in three (SupT1) and two (MT2) independent infections.
FIG. 7. RT activity of the mutant and revertant viruses. The virion-
extracted enzymes were analyzed in the colorimetric poly(A)–oligo(dT)
assay (see Materials and Methods). See Fig. 3 for further details. We
show the average values of two independent transfections, of which
the RT activity was measured in duplicate.Several RT mutations were observed more than once
(residue 157 in culture 5 and 8, 176 in 2 and 5, 284 in 6
and 8). Most strikingly, several of the changes that we
selected in vitro have also been observed in drug-resis-
tant patient isolates. This includes P25A and V179I in
culture 3, I135V and T165I in culture 4 (also coupled in
several clinical samples), V35I in culture 6, and P157S/T
in cultures 5 and 8. Furthermore, several changes that
we selected coincide with residues that have been im-
plicated in drug-resistance. F116L in culture 2 is similar
to the AZT-resistance mutation F116Y. P176S/L in cul-
tures 2 and 5 is similar to the TIBO-resistance mutation
P176T, and S163N is similar to the S163C/T change
observed in patients receiving multiple nucleoside ana-
logues. Because we selected the variants without AZT
pressure, these mutations are not likely to contribute to
improved drug resistance, but rather to restored RT en-
zyme function and virus replication. These combined
results suggest that several mutations observed in
treated patients are not selected to improve the resis-
tance phenotype. Instead, we propose that some of the
secondary changes within the RT protein may be se-
lected primarily to improve RT enzyme function and virus
replication.
Improved virus replication was demonstrated for the
S163N mutation of culture 6 that was introduced in the
41-70 molecular clone. It is likely that many of the other
second-site mutations observed in our in vitro evolution
experiments and in AZT-treated patients improve virus
replication. For instance, our RT enzyme assays and
virus replication studies indicate that the 215 change can
also largely compensate for the replication defect of the
41-70 double mutant. We realize that the situation is even
more complex because the 215 mutation also improves
the level of AZT resistance. Thus, a complex interplay of
different selective forces drive the evolution of AZT-drug
nd MT2 cells (right). See Fig. 2 for details. Similar results were obtained(left) aresistance. A similar multistep evolution of primary re-
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has been proposed for protease resistance (reviewed in
Berkhout, 1999).
Many second-site changes cluster in the fingers–palm
domains near the catalytic core of RT (Fig. 5B). Even
residues at the tip of the fingers (I135V) may approach
the catalytic core of the p66 subunit as part of the p51
subunit, as was demonstrated for the TSAO-resistance
mutation at residue 138 (Jonckheere et al., 1994). Among
the amino acid changes observed in the 41-70 evolution
experiments, many substitutions are at residues that are
implicated in the interaction either with the incoming
nucleotide (residue 116) or with the template strand [res-
idue 157 (observed in cultures 5 and 8), 280, 284 (in 6 and
8), and 447]. Other changes are adjacent to amino acid
positions that are known to interact with the template (25
next to 24, 283 next to 280/284/285/286, 358 next to 359).
These preliminary results may suggest that changes in
the RT-template interaction may improve the polymerase
function of the 41-70 double mutant.
The relatively strong fitness effects of the AZT-resis-
tance mutations may also explain the ongoing evolution
of such strains without AZT that is either upon termina-
tion of AZT treatment or upon transmission of an AZT-
resistant variant. Within individual patients, the wt virus
usually reappears after some time (Boucher et al., 1993).
n situations where persons are infected with an AZT-
esistant virus, continuous evolution at some of the re-
istance positions has also been documented (Yerly et
l., 1998; Goudsmit et al., 1998). This ongoing evolution of
AZT-resistant viruses without drug is very similar to the
situation described for protease drug-resistant HIV-1
variants (Borman et al., 1996). Drug resistance comes at
a price in both scenarios, that is the loss of virus repli-
cation capacity, and the resistant HIV-1 variants therefore
strive to improve this defect by selection of compensa-
tory mutations.
Repair of a mutant RT enzyme by a second-site muta-
tion was recently described for an HIV-1 mutant with the
Y115W mutation (Olivares et al., 1999). A similar genetic
flexibility has been described in studies with HIV-1 mu-
tants with changes in the envelope or integrase protein
(Freed and Martin, 1995; Taddeo et al., 1996). An enor-
mous genetic flexibility and repair potential was also
apparent in detailed evolutionary studies with HIV-1 vari-
ants with changes in critical RNA motifs (Klaver and
Berkhout, 1994). However, other HIV-1 functions, e.g., the
small Tat trans-activator protein, show much less evolu-
tionary flexibility in such mutant-revertant analyses (Ver-
hoef and Berkhout, 1999). The results described in this
paper illustrate the adaptive potential of HIV-1 as resto-
ration of virus replication of the 41-70 mutant can be
accomplished by several, unrelated amino acid substi-
tutions at secondary sites within the RT enzyme.MATERIALS AND METHODS
Cells and viruses
C33A cervix carcinoma cells (ATCC HTB31; Yarchoan
et al., 1994) were grown as a monolayer in Dulbecco’s
minimal essential medium supplemented with 10% (v/v)
fetal calf serum (FCS), 20 mM glucose, and minimal
essential medium nonessential amino acids at 37°C and
in 5% CO2. C33A cells were transfected by the calcium
phosphate method as described previously (Das et al.,
1999). The human T-lymphocyte cell lines SupT1 (Smith
et al., 1984) and MT2 were cultured in RPMI 1640 (GIBCO
BRL) supplemented with 10% FCS. Transfections were
performed with a Bio-Rad Gene Pulser as described
previously (Jeeninga et al., 2000). Peripheral blood mono-
nuclear cells (PBMC) were prepared by Ficoll–Paque
(Pharmacia Biotech) density gradient centrifugation of
heparinized blood from three HIV-1 seronegative individ-
uals. The mix was stimulated for 2 days with PHA (1
mg/ml) in RPMI 1640 supplemented with 10% FCS. The
cells were washed before infection and subsequently
cultured in RPMI supplemented with 10% lymphocult IL2.
Virus competition
Two virus stocks were mixed in a fixed ratio based on
their CA-p24 values, and we used 5 ng CA-p24 to infect
cells. A sample of infected cells was taken after 24 h to
verify the input ratio. For SupT1 cells, subsequent pas-
sages were performed at peak infection as judged by
HIV-induced syncytia. New infections were started with
100 ml culture supernatant. For PBMC, cell samples were
taken after 7 days and 1 ml culture supernatant was used
to infect fresh PBMC. Total cellular chromosomal DNA
was isolated as described previously (Das et al., 1997),
and the HIV-1 RT region with the respective mutations
was PCR-amplified. The PCR product was sequenced
with a DYEnamic cycle-sequencing kit (Amersham,
Cleveland, OH) on an automatic sequencer (Applied Bio-
systems DNA Sequencer 373A). The ratio of the two
viruses was determined by comparing the peak volumes
of the mixed sequence at the altered nucleotide position.
CA-p24 measurements
Culture supernatant was heat inactivated at 56°C for
30 min in the presence of 0.05% Empigen-BB (Calbio-
chem, La Jolla, CA). CA-p24 concentration was deter-
mined by a twin-site ELISA with D7320 (Biochrom, Berlin,
Germany) as the capture antibody, alkaline phosphatase-
conjugated anti-p24 monoclonal antibody (EH12-AP), and
the AMPAK amplification system (Dako Diagnostics) as
described previously (McKeating et al., 1991). Recombi-
nant CA-p24 expressed in a baculovirus system was
used as the reference standard.
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HXB-2 molecular clones with the various AZT-resis-
tance mutations were generated by site-directed mu-
tagenesis. Recombinant viruses were made by the ho-
mologous recombination approach as described
(Boucher et al., 1996). Sequencing of the various rever-
tants and clones was performed on appropriate PCR
fragments with a DYEnamic direct sequencing kit (Am-
ersham) on an automatic sequencer (Applied Biosys-
tems DNA Sequencer 377A). A HXB2 molecular clone in
which an unique XbaI restriction site was created by
introducing a silent mutation in codon 2 of the integrase
gene was used for subcloning of the S163N revertant.
First, we made a pBluescript derivative with the HXB2
ApaI–XbaI fragment encoding the complete RT gene. A
pBluescript/ApaI–XbaI derivative with the 41-70 mutation
was made by replacing the wild-type (wt) BalI–XbaI frag-
ment (amino acids 24–560) for the 41-70 mutant BalI–
XbaI fragment. Second, we exchanged the wt BstXI–
BstXI fragment (amino acids 151–221) from pBluescript/
ApaI–XbaI and pBluescript/ApaI–XbaI/41-70 for the BstXI
fragment obtained from a PCR-amplified RT segment of
the no. 6 recombinant virus. In this way, we exclusively
transferred the Ser163Asn mutation of the no. 6 revertant.
The resulting plasmids were digested with ApaI and
XbaI, and the RT fragments were cloned into a wt HXB2
clone that was digested with the same enzymes. For this
purpose, an additional ApaI site present in the flanking
cellular sequences of the molecular HXB2 clone was
removed by partial ApaI digestion, removal of the pro-
truding ends with Klenow polymerase and religation. All
DNA constructs were verified by sequence analysis.
Reverse transcriptase assays
The RT enzyme was released from virions by NP-40
treatment (0.5% final concentration) of the culture super-
natant or concentrated virus that was pelleted by ultra-
centrifugation. The standard assay conditions were pre-
viously described (Back et al., 1996). In brief, mixtures
contained 60 mM Tris (pH 7.8), 75 mM KCl, 5 mM MgCl2,
.1% NP-40, 1 mM EDTA, 5 mg/ml poly(A)7000, 0.16 mg/ml
ligo(dT)15, 4 mM dithiothreitol (DTT), and 50 mCi/ml
[32P]dTTP (3000 Ci/mmol). Samples were incubated at
7°C and 10 ml aliquots were taken after 1 and 2 h and
spotted onto DAE 81 paper (Whatman). The filter was
washed 3 times in 5% Na2HPO4, dried after two 96%
ethanol washes, and spots were quantitated on a Phos-
phorImager (Molecular Dynamics).
The RT activity was also measured with the Lenti-RT
(magnesium-dependent) activity assay from Cavidi Tech
(Malmsten et al., 1998). Briefly, poly(A) was covalently
coupled to the wells of 96-well microtiter plate and used
for the incorporation of the nucleotide analogue 5-bro-
modeoxyuridine 59 triphosphate (BrdUTP) onto an
oligo(dT)22 primer for 3 and 16 h. Incorporated BrdUMPwas quantitatively detected immunologically with alka-
line phosphatase-conjugated anti-BrdU monoclonal an-
tibody and para-nitrophenyl phosphate as substrate for
color detection at 405 nm after 2 min, 20 min, and 2 h.
Measurements within in the linear range of the Bio-Rad
reader were used to calculate the RT activity, which was
corrected for the amount of input virus (on the basis of
CA-p24 values), and compared with the activity of the wt
enzyme.
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